EGF and malaria: Notwithstanding these caveats, our data clearly demonstrate that the mRNA/LNP platform is very effective for a blood-stage malaria vaccine in which protection depends on the induction of merozoite neutralizing antibodies that recognize the disulfide-bond-dependent, double-EGF-like domains of PyMSP119 and PyMSP8.